Conference
Abstract CT131: A randomized (RCT) phase II study of oncolytic reovirus (pelareorep ) plus standard weekly paclitaxel (P) as therapy for metastatic breast cancer (mBC)
Abstract
Abstract
Background: Pelareorep is a Dearing strain of reovirus serotype 3, with demonstrated in vitro and in vivo activity in many cancers and synergistic cytotoxic activity with microtubule targeting agents, including taxanes. This study was designed to determine the efficacy and safety of pelareorep + P compared to P alone in mBC. Materials and Methods: This randomized, open-label, phase II study enrolled subjects who had …
Authors
Bernstein V; Ellard S; Dent SF; Gelmon KA; Dhesy-Thind SK; Mates M; Salim M; Panasci L; Song X; Clemons M
Volume
77
Pagination
pp. ct131-ct131
Publisher
American Association for Cancer Research (AACR)
Publication Date
July 1, 2017
DOI
10.1158/1538-7445.am2017-ct131
Conference proceedings
Cancer Research
Issue
13_Supplement
ISSN
0008-5472